Cagent Vascular, a leader in endovascular technologies, has announced two milestones: the successful completion of first human-use cases with the Serranator® SONIC Intravascular Lithotripsy (IVL) System and the closing of a $41 million Series D financing round.

The $41 million Series D, co-led by U.S. Venture Partners (USVP) and Astoria Health Investors, funds the global REMODEL II pivotal trial and commercial launch of the SONIC IVL System. The round builds on a commercial foundation already established; Cagent Vascular's Serranator® portfolio is sold nationally across most major U.S. markets, and select major international markets. Proceeds will also fund the Company's SONIC IVL coronary artery platform.

Cagent Vascular is redefining balloon angioplasty with Serration Remodeling Therapy (SRT). Cagent Vascular is the first and only company to commercialize an angioplasty balloon featuring integrated serrations. Their mission is to elevate vessel preparation and treatment outcomes for patients with Peripheral Artery Disease (PAD) and Chronic Limb-Threatening Ischemia (CLTI).